Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal

Alzheimer’s community stakeholders are planning a unified response to a CMS Medicare coverage proposal that would, in their view, disastrously constrain use of PET imaging, and imaging agents like Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.